Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-13
DOI
10.3389/fonc.2021.628456
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
- (2020) Daniel K. Wells et al. CELL
- Determination of human γδ T cell–mediated cytotoxicity using a non-radioactive assay system
- (2019) Mohammed S.O. Tagod et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Neoantigen-directed immune escape in lung cancer evolution
- (2019) Rachel Rosenthal et al. NATURE
- Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
- (2019) Fangjun Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Determinants for Neoantigen Identification
- (2019) Andrea Garcia-Garijo et al. Frontiers in Immunology
- Improved methods for predicting peptide binding affinity to MHC class II molecules
- (2018) Kamilla Kjaergaard Jensen et al. IMMUNOLOGY
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Actively personalized vaccination trial for newly diagnosed glioblastoma
- (2018) Norbert Hilf et al. NATURE
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- (2018) Derin B. Keskin et al. NATURE
- NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data
- (2017) Vanessa Jurtz et al. JOURNAL OF IMMUNOLOGY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- HSP70L1-mediated intracellular priming of dendritic cell vaccination induces more potent CTL response against cancer
- (2016) Shuxun Liu et al. Cellular & Molecular Immunology
- Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition
- (2016) Barbara Melosky et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer
- (2016) Takahiro Karasaki et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
- (2016) Shu Su et al. Scientific Reports
- Sipuleucel-T (Provenge®)—Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention
- (2015) Szymon Jarosławski et al. BIODRUGS
- Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides
- (2015) Weihong Sun et al. CANCER LETTERS
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- OptiType: precision HLA typing from next-generation sequencing data
- (2014) András Szolek et al. BIOINFORMATICS
- A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer
- (2014) Christian Dittrich et al. EUROPEAN JOURNAL OF CANCER
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- RazerS 3: Faster, fully sensitive read mapping
- (2012) David Weese et al. BIOINFORMATICS
- Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine
- (2012) Masanori Noguchi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Adoptive Transfer of Cytotoxic T Lymphocytes Targeting Two Different Antigens Limits Antigen Loss and Tumor Escape
- (2012) Karen M. Kaluza et al. HUMAN GENE THERAPY
- Fast and accurate short read alignment with Burrows-Wheeler transform
- (2009) H. Li et al. BIOINFORMATICS
- Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing
- (2009) Andreas Gnirke et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search